Due to an improved antioxidant mechanism, pioglitazone has also been proposed and trialed as a therapy for Friedreich’s ataxia, a rare neurological disorder arising from recessive genetic inheritance of a mutated Frataxin (FXN) gene on chromosome 9q13 (NCT00811681). This evidence concerns the gene FXN and nervous system disorder.